Suspected Erythroderma
Generalized erythema involving >90% body surface area with scaling
All Pathways
DermatologyEmergency
Erythroderma (Exfoliative Dermatitis) Emergency Management
Erythroderma (Exfoliative Dermatitis) Emergency Management: Suspected Erythroderma → Recognize Life-Threatening Features → Initial Stabilization → Focus...
Pathway Overview
14 steps
Algorithm Steps
14 total
01Start 02Action Recognize Life-Threatening Features
Erythroderma causes significant physiologic stress
- Massive cutaneous vasodilation → hypotension
- Transepidermal water loss → dehydration
- Heat loss → hypothermia risk
- Protein loss → hypoalbuminemia
- Secondary infection risk → sepsis
- Mortality: ~18%
03Action Initial Stabilization
Supportive care is foundation of treatment
- IV access and fluid resuscitation
- Monitor vital signs, urine output
- Warm environment (30-32°C) to prevent hypothermia
- Emollients to reduce transepidermal water loss
- Electrolyte replacement (K+, Na+, Mg2+)
- Nutritional support (high protein)
04Action Focused History
Determine underlying etiology
- Pre-existing dermatosis? (psoriasis, eczema, seborrheic)
- New medications in past 2-6 weeks?
- Malignancy history? Lymphoma symptoms?
- Duration and progression of symptoms
- Prior episodes?
05Decision Determine Etiology
Common causes of erythroderma
- Pre-existing dermatosis: 50-60% (psoriasis most common)
- Drug reaction: 15-20%
- Malignancy (CTCL/Sézary): 10-15%
- Idiopathic: 20-30%
- Other: Contact dermatitis, pemphigus, pityriasis rubra pilaris
06Action Diagnostic Workup
Laboratory and biopsy evaluation
- CBC: Leukocytosis, eosinophilia, Sézary cells
- CMP: Electrolytes, renal function, albumin
- LFTs: Hepatic involvement
- Skin biopsy: Multiple sites recommended
- Blood cultures if febrile
- Consider: LDH, flow cytometry (lymphoma), HIV
07Action Erythrodermic Psoriasis
Known psoriasis with generalized flare
- AVOID systemic steroids (rebound flare)
- Cyclosporine 3-5 mg/kg/day
- Or methotrexate, infliximab
- Topical emollients, gentle care
08Action Ongoing Supportive Care
Continue regardless of etiology
- Gentle skin care: Warm baths, emollients
- Topical steroids (medium-high potency) for symptom relief
- Wet wraps for severe symptoms
- Antihistamines for pruritus
- Monitor for secondary infection
- VTE prophylaxis if hospitalized
- Nutritional support
09Warning Secondary Infection
Disrupted skin barrier increases risk
- Monitor for S. aureus, streptococcal infection
- Fever, increased erythema, purulence
- Blood cultures, wound cultures
- Empiric antibiotics covering skin flora
10Outcome Disease Controlled
Resolution with appropriate treatment
- Gradual improvement over weeks
- Continued treatment of underlying cause
- Dermatology follow-up essential
- May require long-term maintenance therapy
- Path rejoins step 10Shared downstream outcome
11Warning Complications / Death
High mortality if untreated
- Sepsis, multi-organ failure
- Cardiac failure (high-output)
- Overall mortality ~18%
- ICU transfer if hemodynamically unstable
12Action Drug-Induced
Recent medication exposure
- STOP causative drug immediately
- Systemic corticosteroids may help
- Rule out SJS/TEN overlap
- Common: Allopurinol, anticonvulsants, CCBs, antibiotics
- Path rejoins step 08Shared downstream outcome
13Warning CTCL / Sézary Syndrome
Cutaneous T-cell lymphoma
- Sézary cells on blood smear or flow cytometry
- Refer to hematology/oncology
- Phototherapy, systemic therapies
- Poor prognosis without treatment
- Path rejoins step 08Shared downstream outcome
14Action Other Dermatoses
Treat underlying condition
- Atopic dermatitis: Steroids, cyclosporine, dupilumab
- Seborrheic: Antifungals, steroids
- Pemphigus foliaceus: Steroids, rituximab
- Pityriasis rubra pilaris: Retinoids
- Path rejoins step 08Shared downstream outcome
Guideline Source
Erythroderma: A Dermatologic Emergency
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Underlying etiology may be difficult to determine acutely
- Skin biopsy may be non-diagnostic in early stages
- Treatment depends heavily on underlying cause
- Avoid systemic steroids in psoriasis and SSSS
- May mask underlying malignancy
Applicable Regions
USEU
Version 1Next review: 2027-01-11
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Erythroderma (Exfoliative Dermatitis) Emergency Management?
The Erythroderma (Exfoliative Dermatitis) Emergency Management is a emergency clinical algorithm for Dermatology. It provides a structured decision tree to guide clinical decision-making, based on Erythroderma: A Dermatologic Emergency.
What guideline is the Erythroderma (Exfoliative Dermatitis) Emergency Management based on?
This algorithm is based on Erythroderma: A Dermatologic Emergency (DOI: 10.1017/S1481803500009052).
What are the limitations of the Erythroderma (Exfoliative Dermatitis) Emergency Management?
Known limitations include: Underlying etiology may be difficult to determine acutely; Skin biopsy may be non-diagnostic in early stages; Treatment depends heavily on underlying cause; Avoid systemic steroids in psoriasis and SSSS; May mask underlying malignancy. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Erythroderma (Exfoliative Dermatitis) Emergency Management appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free